Boehringer Ingelheim Animal Health Canada Inc.
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Vetoquinol
ZyCoV-D Merial |
| gptkbp:awards |
Best_Workplace_in_Canada
Top_Employer_in_Canada |
| gptkbp:communityInvolvement |
Educational programs
Sponsorships Animal welfare initiatives |
| gptkbp:employees |
100-200
|
| gptkbp:financials |
Investment in R&D
Revenue over $1 billion Strong growth rate |
| gptkbp:focus |
Animal health
|
| gptkbp:founded |
2000
|
| gptkbp:globalPresence |
International collaborations
Export activities Operations in over 100 countries |
| gptkbp:headquarters |
gptkb:Canada
|
| gptkbp:history |
Founded in 1885
Expansion into animal health in 2000 Launch of new vaccines in 2020 Acquisition_of_Merial_in_2015 Acquisition_of_Vetoquinol_in_2019 |
| https://www.w3.org/2000/01/rdf-schema#label |
Boehringer Ingelheim Animal Health Canada Inc.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:innovation |
Clinical trials
Biologics New product development Veterinary diagnostics Digital_health_solutions |
| gptkbp:leadership |
Management team
Board_of_Directors CEO_-_Hubertus_von_Baumbach |
| gptkbp:market |
gptkb:Canada
|
| gptkbp:parentCompany |
gptkb:Boehringer_Ingelheim_GmbH
|
| gptkbp:partnerships |
Research institutions
Veterinary schools |
| gptkbp:products |
Antibiotics
Vaccines Antiparasitics |
| gptkbp:researchFocus |
Animal diseases
|
| gptkbp:services |
Veterinary services
|
| gptkbp:subsidiary |
gptkb:Boehringer_Ingelheim
|
| gptkbp:sustainabilityInitiatives |
Renewable energy usage
Environmental responsibility Waste reduction programs Sustainable sourcing Carbon footprint reduction |
| gptkbp:type |
Private
|
| gptkbp:website |
www.boehringer-ingelheim.ca
|